Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.77
WST's Cash to Debt is ranked lower than
61% of the 202 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. WST: 0.77 )
Ranked among companies with meaningful Cash to Debt only.
WST' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.28 Max: 0.92
Current: 0.77
0.08
0.92
Equity to Asset 0.64
WST's Equity to Asset is ranked higher than
53% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. WST: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
WST' s Equity to Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.45 Max: 0.64
Current: 0.64
0.35
0.64
Interest Coverage 8.86
WST's Interest Coverage is ranked lower than
64% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.76 vs. WST: 8.86 )
Ranked among companies with meaningful Interest Coverage only.
WST' s Interest Coverage Range Over the Past 10 Years
Min: 5.12  Med: 7.15 Max: 10.92
Current: 8.86
5.12
10.92
F-Score: 7
Z-Score: 7.54
M-Score: -2.71
WACC vs ROIC
9.75%
7.95%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 7.77
WST's Operating margin (%) is ranked higher than
58% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.55 vs. WST: 7.77 )
Ranked among companies with meaningful Operating margin (%) only.
WST' s Operating margin (%) Range Over the Past 10 Years
Min: 8.21  Med: 10.50 Max: 12.68
Current: 7.77
8.21
12.68
Net-margin (%) 5.95
WST's Net-margin (%) is ranked higher than
60% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. WST: 5.95 )
Ranked among companies with meaningful Net-margin (%) only.
WST' s Net-margin (%) Range Over the Past 10 Years
Min: 5.91  Med: 6.91 Max: 8.94
Current: 5.95
5.91
8.94
ROE (%) 8.44
WST's ROE (%) is ranked higher than
60% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. WST: 8.44 )
Ranked among companies with meaningful ROE (%) only.
WST' s ROE (%) Range Over the Past 10 Years
Min: 10.84  Med: 13.69 Max: 17.79
Current: 8.44
10.84
17.79
ROA (%) 5.11
WST's ROA (%) is ranked higher than
64% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. WST: 5.11 )
Ranked among companies with meaningful ROA (%) only.
WST' s ROA (%) Range Over the Past 10 Years
Min: 5.09  Med: 6.44 Max: 7.66
Current: 5.11
5.09
7.66
ROC (Joel Greenblatt) (%) 12.49
WST's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.53 vs. WST: 12.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
WST' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 12.75  Med: 17.67 Max: 22.57
Current: 12.49
12.75
22.57
Revenue Growth (3Y)(%) 6.60
WST's Revenue Growth (3Y)(%) is ranked higher than
58% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.10 vs. WST: 6.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
WST' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.3  Med: 5.40 Max: 17.2
Current: 6.6
-2.3
17.2
EBITDA Growth (3Y)(%) 14.50
WST's EBITDA Growth (3Y)(%) is ranked higher than
69% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. WST: 14.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
WST' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.6  Med: 10.40 Max: 20.3
Current: 14.5
-15.6
20.3
EPS Growth (3Y)(%) 19.60
WST's EPS Growth (3Y)(%) is ranked higher than
74% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. WST: 19.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
WST' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.3  Med: 19.10 Max: 169.5
Current: 19.6
-65.3
169.5
» WST's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

WST Guru Trades in Q2 2015

Ron Baron 2,543,961 sh (+0.22%)
Ruane Cunniff 1,015,951 sh (-0.61%)
Ken Fisher 1,292,202 sh (-1.39%)
Jim Simons 833,800 sh (-7.68%)
RS Investment Management 1,532,061 sh (-20.81%)
» More
Q3 2015

WST Guru Trades in Q3 2015

RS Investment Management 1,785,295 sh (+16.53%)
Ruane Cunniff 1,009,579 sh (-0.63%)
Ron Baron 2,480,237 sh (-2.50%)
Ken Fisher 1,249,108 sh (-3.33%)
Jim Simons 598,500 sh (-28.22%)
» More
Q4 2015

WST Guru Trades in Q4 2015

RS Investment Management 1,921,695 sh (+7.64%)
Ken Fisher 1,240,153 sh (-0.72%)
Ruane Cunniff 991,928 sh (-1.75%)
Ron Baron 2,367,992 sh (-4.53%)
Jim Simons 514,500 sh (-14.04%)
» More
Q1 2016

WST Guru Trades in Q1 2016

Paul Tudor Jones 4,400 sh (New)
Columbia Wanger 317,164 sh (New)
Jim Simons 514,200 sh (-0.06%)
Ken Fisher 1,228,363 sh (-0.95%)
Ron Baron 2,310,171 sh (-2.44%)
RS Investment Management 1,586,533 sh (-17.44%)
Ruane Cunniff 533,650 sh (-46.20%)
» More
» Details

Insider Trades

Latest Guru Trades with WST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:WAT, NYSE:MTD, NAS:HOLX, NYSE:RMD, NYSE:COO, NAS:SIRO » details
Traded in other countries:WPS.Germany,
West Pharmaceutical Services Inc is a manufacturer of components & systems for injectable drug delivery, plastic packaging, delivery system components. Its products include stoppers and seals for vials, prefillable syringe components and systems.

West Pharmaceutical Services Inc was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923. The Company is a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. Majority of its business is conducted in healthcare markets. Its reportable segments are Packaging Systems and Delivery Systems. Packaging Systems develops, manufactures and sells primary packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. Delivery Systems develops, manufactures and sells safety and administration systems, multi-component systems for drug administration, and custom contract-manufacturing solutions targeted to the healthcare and consumer-products industries. In addition, Delivery Systems is responsible for the continued development and commercialization of the Companys line of proprietary healthcare, administrative and advanced injection systems, including Daikyo CZ, SmartDose and other systems. Packaging Systems has three operating segments: the Americas, Europe and Asia Pacific. The Company competes with several companies across its major product lines. Competition is based mainly on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost control programs across their entire operations. The design, development, manufacturing, marketing and labeling of certain of the Companys products and its customers products that incorporate its products are subject to regulation by governmental authorities in the United States, Europe and other countries, including the FDA and the European Medicines Agency.

Guru Investment Theses on West Pharmaceutical Services Inc

Baron Funds Comments on West Pharmaceutical Services - Apr 26, 2016

West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years.



From Baron Asset Funds' first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about West Pharmaceutical Services Inc

Baron Funds Comments on West Pharmaceutical Services Guru stock highlight
West Pharmaceutical Services, Inc. (NYSE:WST) manufactures components and systems for the packaging and delivery of injectable drugs. West’s shares gained during the quarter after reporting strong financial results and providing solid earnings guidance for 2016. West’s products are frequently “designed in” as part of the regulatory approval process for its clients’ drugs, which makes it quite difficult for West’s products to be displaced throughout a drug’s lifecycle. There is a substantial development pipeline of injectable biologic drugs, and we believe this will allow West to experience double-digit growth rates in its main market for at least the next several years. We also believe that West will benefit from the increased sale of high-margin proprietary products, including newly-developed plastic syringes and wearable injectors for a new generation of high volume, high viscosity drugs. As a result, we believe that company has the potential to double its earnings during the next five years. Read more...
Weekly CEO Buys Highlight: WST, PHII, CLMS, CSBK, AMRC
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 64.40
WST's P/E(ttm) is ranked lower than
83% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.16 vs. WST: 64.40 )
Ranked among companies with meaningful P/E(ttm) only.
WST' s P/E(ttm) Range Over the Past 10 Years
Min: 12.43  Med: 22.36 Max: 64.4
Current: 64.4
12.43
64.4
Forward P/E 27.40
WST's Forward P/E is ranked lower than
87% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.96 vs. WST: 27.40 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 64.40
WST's PE(NRI) is ranked lower than
83% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.68 vs. WST: 64.40 )
Ranked among companies with meaningful PE(NRI) only.
WST' s PE(NRI) Range Over the Past 10 Years
Min: 12.9  Med: 22.76 Max: 64.4
Current: 64.4
12.9
64.4
Price/Owner Earnings (ttm) 68.36
WST's Price/Owner Earnings (ttm) is ranked lower than
83% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.85 vs. WST: 68.36 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
WST' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 19.16  Med: 34.15 Max: 94.36
Current: 68.36
19.16
94.36
P/B 5.00
WST's P/B is ranked lower than
72% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. WST: 5.00 )
Ranked among companies with meaningful P/B only.
WST' s P/B Range Over the Past 10 Years
Min: 1.74  Med: 2.77 Max: 5
Current: 5
1.74
5
P/S 3.85
WST's P/S is ranked lower than
64% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. WST: 3.85 )
Ranked among companies with meaningful P/S only.
WST' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 1.50 Max: 3.85
Current: 3.85
1.02
3.85
PFCF 70.78
WST's PFCF is ranked lower than
95% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.49 vs. WST: 70.78 )
Ranked among companies with meaningful PFCF only.
WST' s PFCF Range Over the Past 10 Years
Min: 18.53  Med: 41.22 Max: 381.09
Current: 70.78
18.53
381.09
POCF 25.14
WST's POCF is ranked lower than
75% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.58 vs. WST: 25.14 )
Ranked among companies with meaningful POCF only.
WST' s POCF Range Over the Past 10 Years
Min: 7.55  Med: 11.82 Max: 25.14
Current: 25.14
7.55
25.14
EV-to-EBIT 48.64
WST's EV-to-EBIT is ranked lower than
83% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.36 vs. WST: 48.64 )
Ranked among companies with meaningful EV-to-EBIT only.
WST' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.2  Med: 18.30 Max: 48.64
Current: 48.64
11.2
48.64
EV-to-EBITDA 26.97
WST's EV-to-EBITDA is ranked lower than
75% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.91 vs. WST: 26.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
WST' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.6  Med: 11.40 Max: 26.97
Current: 26.97
7.6
26.97
PEG 5.31
WST's PEG is ranked lower than
82% of the 60 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.58 vs. WST: 5.31 )
Ranked among companies with meaningful PEG only.
WST' s PEG Range Over the Past 10 Years
Min: 1.01  Med: 2.18 Max: 27.13
Current: 5.31
1.01
27.13
Shiller P/E 57.46
WST's Shiller P/E is ranked lower than
77% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 37.39 vs. WST: 57.46 )
Ranked among companies with meaningful Shiller P/E only.
WST' s Shiller P/E Range Over the Past 10 Years
Min: 20.37  Med: 34.60 Max: 57.46
Current: 57.46
20.37
57.46
Current Ratio 2.62
WST's Current Ratio is ranked higher than
52% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. WST: 2.62 )
Ranked among companies with meaningful Current Ratio only.
WST' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 2.20 Max: 3.1
Current: 2.62
1.45
3.1
Quick Ratio 1.81
WST's Quick Ratio is ranked higher than
54% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. WST: 1.81 )
Ranked among companies with meaningful Quick Ratio only.
WST' s Quick Ratio Range Over the Past 10 Years
Min: 1.09  Med: 1.57 Max: 2.28
Current: 1.81
1.09
2.28
Days Inventory 71.24
WST's Days Inventory is ranked higher than
83% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.83 vs. WST: 71.24 )
Ranked among companies with meaningful Days Inventory only.
WST' s Days Inventory Range Over the Past 10 Years
Min: 45.99  Med: 61.68 Max: 67.18
Current: 71.24
45.99
67.18
Days Sales Outstanding 53.65
WST's Days Sales Outstanding is ranked higher than
67% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.25 vs. WST: 53.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
WST' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.76  Med: 46.96 Max: 56.03
Current: 53.65
41.76
56.03
Days Payable 37.20
WST's Days Payable is ranked lower than
70% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 55.30 vs. WST: 37.20 )
Ranked among companies with meaningful Days Payable only.
WST' s Days Payable Range Over the Past 10 Years
Min: 29.33  Med: 36.36 Max: 42.74
Current: 37.2
29.33
42.74

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.64
WST's Dividend Yield is ranked lower than
77% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. WST: 0.64 )
Ranked among companies with meaningful Dividend Yield only.
WST' s Dividend Yield Range Over the Past 10 Years
Min: 0.63  Med: 1.32 Max: 2.01
Current: 0.64
0.63
2.01
Dividend Payout 0.40
WST's Dividend Payout is ranked higher than
61% of the 96 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.37 vs. WST: 0.40 )
Ranked among companies with meaningful Dividend Payout only.
WST' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.30 Max: 5.5
Current: 0.4
0.14
5.5
Dividend Growth (3y) 5.90
WST's Dividend Growth (3y) is ranked lower than
73% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.90 vs. WST: 5.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
WST' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 5.2  Med: 6.35 Max: 8.2
Current: 5.9
5.2
8.2
Forward Dividend Yield 0.66
WST's Forward Dividend Yield is ranked lower than
80% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.46 vs. WST: 0.66 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.86
WST's Yield on cost (5-Year) is ranked lower than
77% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.89 vs. WST: 0.86 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
WST' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.84  Med: 1.77 Max: 2.69
Current: 0.86
0.84
2.69
3-Year Average Share Buyback Ratio -1.90
WST's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.90 vs. WST: -1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WST' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4  Med: -1.00 Max: 4.8
Current: -1.9
-4
4.8

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 148.06
WST's Price/Net Current Asset Value is ranked lower than
98% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.97 vs. WST: 148.06 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
WST' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 138.64  Med: 571.16 Max: 2007.33
Current: 148.06
138.64
2007.33
Price/Tangible Book 5.68
WST's Price/Tangible Book is ranked lower than
61% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.63 vs. WST: 5.68 )
Ranked among companies with meaningful Price/Tangible Book only.
WST' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.73  Med: 3.09 Max: 6.87
Current: 5.68
1.73
6.87
Price/Projected FCF 3.39
WST's Price/Projected FCF is ranked lower than
75% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. WST: 3.39 )
Ranked among companies with meaningful Price/Projected FCF only.
WST' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 2.27 Max: 3.17
Current: 3.39
0.97
3.17
Price/DCF (Earnings Based) 4.69
WST's Price/DCF (Earnings Based) is ranked lower than
95% of the 19 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.83 vs. WST: 4.69 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 2.56
WST's Price/Median PS Value is ranked lower than
94% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.04 vs. WST: 2.56 )
Ranked among companies with meaningful Price/Median PS Value only.
WST' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.45  Med: 0.87 Max: 2.39
Current: 2.56
0.45
2.39
Price/Peter Lynch Fair Value 4.60
WST's Price/Peter Lynch Fair Value is ranked lower than
84% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.34 vs. WST: 4.60 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
WST' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.76  Med: 1.84 Max: 76.88
Current: 4.6
0.76
76.88
Price/Graham Number 4.03
WST's Price/Graham Number is ranked lower than
74% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. WST: 4.03 )
Ranked among companies with meaningful Price/Graham Number only.
WST' s Price/Graham Number Range Over the Past 10 Years
Min: 0.97  Med: 1.84 Max: 7.88
Current: 4.03
0.97
7.88
Earnings Yield (Greenblatt) (%) 2.06
WST's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. WST: 2.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
WST' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.06  Med: 5.50 Max: 8.9
Current: 2.06
2.06
8.9
Forward Rate of Return (Yacktman) (%) 14.97
WST's Forward Rate of Return (Yacktman) (%) is ranked higher than
75% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.42 vs. WST: 14.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
WST' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3.6  Med: 10.60 Max: 18.4
Current: 14.97
-3.6
18.4

More Statistics

Revenue (TTM) (Mil) $1,426
EPS (TTM) $ 1.15
Beta1.11
Short Percentage of Float4.60%
52-Week Range $52.79 - 74.22
Shares Outstanding (Mil)73.08

Analyst Estimate

Dec16 Dec17
Revenue (Mil $)
EPS ($) 2.13 2.64
EPS without NRI ($) 2.13 2.64
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for WST

Headlines

Articles On GuruFocus.com
Baron Funds Comments on West Pharmaceutical Services Apr 26 2016 
Baron Asset Fund 1st Quarter Commentary Apr 26 2016 
Weekly CEO Buys Highlight: WST, PHII, CLMS, CSBK, AMRC May 26 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Is Cooper Companies' Upward Trend Likely to Go On? Mar 25 2014 
Illumina Inc: How Long Can a Miracle Go On? Feb 07 2014 
Buy ResMed and Sleep Tight (Like Jim Simons) Feb 02 2014 
The Best Dividends on April 16, 2012 Apr 13 2012 
West Pharmaceutical Services Inc. Reports Operating Results (10-K) Feb 28 2011 
West Pharmaceutical Services Inc. (WST) COO & President Steven A Ellers sells 10,000 Shares Feb 24 2010 

More From Other Websites
WEST PHARMACEUTICAL SERVICES INC Financials May 12 2016
WEST PHARMACEUTICAL SERVICES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... May 11 2016
WEST PHARMACEUTICAL SERVICES INC Files SEC form 10-Q, Quarterly Report May 06 2016
ETF’s with exposure to West Pharmaceutical Services, Inc. : May 4, 2016 May 04 2016
West to Present at Two Investor Conferences in May May 04 2016
West to Present at Two Investor Conferences in May May 04 2016
West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
Edited Transcript of WST earnings conference call or presentation 28-Apr-16 1:00pm GMT Apr 28 2016
West Pharmaceutical tops Street 1Q forecasts Apr 28 2016
West Pharmaceutical tops Street 1Q forecasts Apr 28 2016
WEST PHARMACEUTICAL SERVICES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 28 2016
West Pharmaceutical Services Inc Earnings Call scheduled for 9:00 am ET today Apr 28 2016
West Announces First Quarter 2016 Results Apr 28 2016
Q1 2016 West Pharmaceutical Services Inc Earnings Release - Before Market Open Apr 28 2016
West Announces First Quarter 2016 Results Apr 28 2016
Chester County firm invests in Israeli microneedle developer Apr 25 2016
West Makes Investment in NanoPass Technologies Apr 25 2016
West Makes Investment in NanoPass Technologies Apr 25 2016
UltimatePlayer Update and Appointment of Broker Apr 14 2016
West to Host First Quarter 2016 Conference Call Apr 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)